Zimmer Biomet reports Q1 adjusted EPS $1.81, consensus $1.77

Reports Q1 revenue $1.91B, consensus $1.9B. “We are proud of our team’s continued execution and performance to start the year, as we delivered solid first quarter results and advanced our bold innovation agenda,” said Ivan Tornos, Zimmer Biomet’s (ZBH) president and CEO. “We’re excited about the momentum in U.S. Hips, fueled by our revamped portfolio inclusive of the Z1 Triple-Taper Femoral Hip System, HAMMR(R) Automated Hip Surgical Impactor System, as well as navigation capabilities, and believe the early enthusiasm from surgeons for our new Oxford Cementless Partial Knee positions us well to accelerate growth in the second half of the year. The recently completed acquisition of Paragon 28 is another bold step toward our innovation and diversification ambitions, expanding our S.E.T. business with leading technologies and a dedicated commercial channel in the high-growth foot and ankle segment.”